|
Life Science Nation Newsletter | October 23, 2014 | Issue 85
|
|
Family Offices Investing in Early Stage Medtech: RESI 4 Announces First Panel
|
IPO's Recycle Cash Back into Life Sciences
READ MORE
|
|
Partnering with Corporate Venture Capital: Tips from Industry Veterans
|
 Life Science Investor Mandates (Oct. 16 - Oct. 22) |
| |
|
Seeking Companies Working with Device Coatings and Nanotechnology
|
|
Looking Opportunistically In the Life Science Space
|
|
Seeking 510k Device Opportunities
|
|
|
|
By Tom Crosby, RESI Conference Manager, LSN
 At the RESI Conference in September, LSN hosted a panel of family office investors that attracted a standing-room-only crowd and received excellent reviews. Given the success of that session, LSN is pleased to announce the first panel for RESI 4 San Francisco, January 13, 2015: Family Offices Investing in Early Stage Medtech. This will run simultaneously with Family Offices Investing in Early Stage Therapeutics, the details of which will be announced at a later date...
This panel spotlights family offices- One of the new categories of investor that has entered the early stage arena vacated by VC. Moderated by Bill Brah, Founder & Executive Director of UMASS Venture Development Center, the panel includes the following speakers:- Alejandra Paradones, CEO & Founder, BSI Capital Group
- Neil Wyant, Managing Director, Everett Partners
- Clay Heighten, Founding Member, Green Park & Golf
- Norm Gitis, Managing Partner, Lymo Investments
|
 |
|
|
Several significant factors have been attracting capital to the life science sector over the past two years. An IPO explosion has provided many life science investors with positive exits, and, in turn, they have established new funds to put some of that capital back to work. In addition, new investors have come to the sector as a result of the number of successful IPOs and low interest rates; investors are looking for better returns. These factors led to life science funds raising an estimated $3.5 billion in 2013 alone. Several funds have continued to raise capital this year.
This is positive news for fundraising entrepreneurs, and their next step should be to pinpoint the funds that have raised new capital and their investment targets.
The LSN research team has identified and interviewed more than 100 investors who have raised new capital since 2012. These investors fall in eight categories...
|
|
|
By Shaoyu Chang, Research Analyst, LSNN
 The role of corporate venture capital (CVC) continued its remarkable expansion in 2014. In the second quarter, CVC funding accounted for 29% of total venture capital funding. In the healthcare sector alone, CVC funding soared to a five-quarter high of $1.4 billion, up 200% from the previous quarter. SR One, Novartis Venture Funds, and Johnson & Johnson Development Corporation led CVC funding in life sciences, while Aduro Biotech, Coherus BioSciences, and Principia BioPharma successfully raised more than $50 million in financing rounds with their CVC partners. CVC funds are an attractive option for life science entrepreneurs for several reasons. Compared with other investors, CVC funds are not only able to provide more capital but also willing to take on riskier projects with promising potential. Working with industry veterans can provide start-ups with critical know-how in areas such as technology design, clinical development, and product commercialization. And in some cases, CVC investments lead to an acquisition or strategic partnership... |
|
|
|
|
|
|
|
|
Editors:
Nono Hu, Senior Manager, Branding & Messaging, LSN
|
|
|
|
